Division of Gastroenterology, Department of Medicine, Walter Reed National Military Medical Center, Washington, DC, USA.
J Viral Hepat. 2014 Jan;21(1):1-8. doi: 10.1111/jvh.12172. Epub 2013 Oct 6.
Chronic hepatitis C (CHC) and nonalcoholic fatty liver disease (NAFLD) have an individual prevalence of 1.8-3% and at least 30%, respectively, in the United States. It is therefore not surprising that there is overlap between these two common chronic liver diseases, although the relationship appears to go beyond isolated co-existence. Hepatic steatosis is a common feature of CHC infection and can be related to both metabolic and viral specific factors. Steatosis in the setting of nongenotype 3 CHC has been predictive of response to therapy prior to the advent of the direct acting antiviral medications (DAAs). Similarly, lipid metabolism appears important in response to CHC treatment. The pathways for both lipid homeostasis and NAFLD as it pertains to CHC infection as well as the utilization of statin therapy in CHC infection will be reviewed with a focus on the relevance of these topics in the era of DAA therapy.
慢性丙型肝炎 (CHC) 和非酒精性脂肪性肝病 (NAFLD) 在美国的个体患病率分别为 1.8-3%和至少 30%。因此，这两种常见的慢性肝病之间存在重叠并不奇怪，尽管这种关系似乎不仅仅是孤立的共存。肝脂肪变性是 CHC 感染的常见特征，可能与代谢和病毒特异性因素有关。非基因型 3 CHC 中的脂肪变性在直接作用抗病毒药物 (DAAs) 问世之前已被预测为对治疗有反应。同样，脂质代谢在 CHC 治疗中似乎很重要。本文将综述脂质稳态和 NAFLD 的途径，以及他汀类药物治疗在 CHC 感染中的应用，重点关注这些在 DAA 治疗时代的相关性。
